Real-world effectiveness and safety of nintedanib in connective tissue disease– associated interstitial lung disease: Retrospective cohort study Romatolojik hastalıklara bağlı interstisyel akciğer hastalıklarında nintedanib: Gerçek yaşam deneyimi


Creative Commons License

Yilmaz A., Bektaş E., DEMİRKOL B., Eren R., İlhan U., ÇETİNKAYA E., ...Daha Fazla

Tuberkuloz ve Toraks, cilt.74, sa.3, ss.127-137, 2026 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 74 Sayı: 3
  • Basım Tarihi: 2026
  • Doi Numarası: 10.5578/tt.2026031271
  • Dergi Adı: Tuberkuloz ve Toraks
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, TR DİZİN (ULAKBİM), Biomedical Reference Collection: Corporate Edition (EBSCO)
  • Sayfa Sayıları: ss.127-137
  • Anahtar Kelimeler: antifibrotic therapy, connective tissue disease, immunosuppressive therapy, interstitial lung disease, Nintedanib, real-life data
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Introduction: Nintedanib, a multi-tyrosine kinase inhibitor, has demonstrated efficacy in reducing lung function decline in progressive fibrosing interstitial lung disease (ILD). However, real-world evidence in heterogeneous connective tissue disease (CTD) –associated ILD populations, particularly under immu-nosuppressive (IS) therapy, remains limited. This study aimed to evaluate the effectiveness, safety, and treatment retention of nintedanib across CTD-ILD. Materials and Methods: Single-center retrospective cohort included 42 patients with CTD-ILD who initiated nintedanib between January 2020-January 2025. Baseline characteristics, pulmonary function tests, radiological findings, adverse events (AEs), and treatment retention were analyzed. Patients were stratified as stable [absence of ≥5% forced vital capacity (FVC) decline] or progressive based on 12-month follow-up. Inter-group comparisons were per-formed. Drug survival was assessed using Kaplan–Meier estimates. Results: The cohort comprised idiopathic pneumonia with autoimmune features (41%), systemic sclerosis (29%), rheumatoid arthritis (19%), and Sjögren’s disease (7%). Nintedanib was initiated after IS in 82% of the cases. Median treatment duration was 17 months. At 12 months, FVC% remained stable [62 (55–73) to 66 (54–76), p= 0.929] and diffusing capacity of the lung for carbon monoxide (DLCO%) showed no significant change [37 (27–54) to 40 (24–45), p= 0.448]. Diarrhea was the most frequent AE (33%), and discontinuation occurred in 6 patients (14%). 12-month retention exceeded 85%. No significant differences were observed between stable (n= 24) and progressive (n= 11) groups. Conclusion: In this real-world cohort, predominantly pretreated with IS, nintedanib was associated with functional stabilization and good tolerability across diverse subtypes. Low rates of diarrhea and high treatment retention support the feasibility of antifibrotic IS integration in progressive CTD-ILD care.